Trials soon ready
Clinical trials expected to report results within the next 12 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Showing the top 50 of 33853 trials in this window.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-breakClarity Pharmaceuticals Ltd ASX: CU6
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-breakSinovac Biotech Co., Ltd. NASDAQ: SVA
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Can a single infusion fix a genetic cause of Sky-High cholesterol?
Cure Recruiting nowThis is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR mutations. NGGT006 is an adeno-associated viral (AAV) …
Results expected Mar 2027 (estimated)
Early phase 1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
CRISPR stem cell therapy could end transfusions for sickle cell and thalassemia patients
Disease control Recruiting nowThis is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSP…
Results expected Jun 2027 (estimated)
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~9 moA large company. One readout moves the needle only so far.
-
One-Time injection aims to restore hearing in children born deaf
Cure OngoingThis study intends to assess safety, tolerability, and efficacy of SENS-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the Otoferlin gene.
Results expected Jul 2027 (estimated)
Phase 1/2 • Sponsor: Sensorion • Aim: Cure
Last updated Jul 10, 2026 00:00 UTC
-
Can a single CAR-T infusion reset the immune system in autoimmune disease?
Cure Recruiting nowThis is a open-label, exploratory trial to evaluate the safety, feasibility, and preliminary efficacy of RN1201, an Allogeneic CAR-T cell therapy, in patients with autoimmune diseases refractory to standard treatment. Eligible patients with moderate to severe activity of diseases…
Results expected Aug 2027 (estimated)
Phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
Result impact 🚀 Make-or-breakVery highSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Why investors are watching
RegenxBio is testing RGX-202, a one-time gene therapy for Duchenne muscular dystrophy, in a 65-patient study that combines phase 2 and phase 3. For a small company, this trial is the main driver of its value, because a positive result could support regulatory approval and a negative result would leave it without a clear path forward.
If it works: If RGX-202 shows it is safe and helps boys with Duchenne, RegenxBio could move closer to bringing the therapy to market. That outcome would validate the company's core science and give it a product to sell.
If it fails: Gene therapy trials often fail on safety or effectiveness, and this one is still in early testing. A failure or delay could leave RegenxBio with no approved product and little reason for investors to stay.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThe hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch\&wait…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThe overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (A…
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One shot, six months of malaria shield? a new trial tests a powerful antibody in children
Prevention OngoingBackground and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and de…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
Result impactVery highSmall-cap Phase 2 Readout in ~1 wkA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is testing a new polio vaccine that uses virus-like particles instead of the traditional live or inactivated virus. This trial checks the vaccine's safety and immune response in infants and toddlers, and a positive result could give the small company a new product in a global market with steady demand. Because CanSino is small, this single trial's outcome can meaningfully affect its value and reputation.
If it works: A successful readout could position CanSino as a leader in next-generation polio vaccines, potentially opening partnerships or licensing deals with larger organizations. It may also validate the company's VLP platform for other vaccines, broadening its pipeline.
If it fails: The trial could fail to show adequate immune response or safety, which would set back the program and hurt investor confidence. Trials at this stage often fail, and any delay in enrollment or dosing could also weigh on the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Can specially trained immune cells flush out hidden HIV?
Cure OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase 1 • Sponsor: Catherine Bollard • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~6 wkA large company. One readout moves the needle only so far.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
May already have reported ↗ AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap May already have reported Readout in ~2 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-16 → -
Can a single radiation dose cure large liver tumors?
Cure Recruiting nowThe RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in pa…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
One-Time gene shot aims to stop bleeding in hemophilia a
Disease control Recruiting nowThis study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
Cure OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
Cure Recruiting nowA study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose. Next, In dose expansion phase, patients were assign two…
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Sichuan University • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
One pill may halt sleeping sickness spread
Disease control Recruiting nowThis protocol describes both the epidemiological study which aims at assessing whether over a three-year period a zero prevalence can be achieved when implementing a screen \& treat approach with acoziborole, as well as a nested clinical study aimed at generating further evidence…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
Cure Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Results expected Dec 2026 (estimated)
Phase 4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Cure Recruiting nowThe purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. · 601607 SSEResult impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
Can a One-Time gene injection ease the burden of wet AMD?
Disease control Recruiting nowThis is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Results expected Jan 2027 (estimated)
Phase 1/2 • Sponsor: Skyline Therapeutics (US) Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Thinking your way to movement: brain-computer interface tested for hand function in tetraplegia
Disease control Recruiting nowThis prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate t…
Results expected Jan 2027 (estimated)
Sponsor: NeuroXess Technology (shanghai) Co.,Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can donor immune cells be engineered to fight blood cancer?
Cure Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Results expected Feb 2027 (estimated)
Phase 1 • Sponsor: University College, London • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Could ketamine be a fast-acting lifeline for suicidal teens and young adults?
Symptom relief Recruiting nowKetamine, an NMDA antagonist, has been shown to have rapid anti- suicidal effects. However, its safety and efficacy and special populations has not been investigated and documented. Several reports in adults suggest rapid decrease of suicidal ideation. In the last decade there is…
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: Tatiana Falcone, MD • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can a single injection reprogram immune cells to fight cancer?
Cure Recruiting nowThis is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with…
Results expected Mar 2027 (estimated)
Phase 1 • Sponsor: Ruijin Hospital • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~5 moA small company. This result carries real weight for it.
Ocugen · OCGN NASDAQ Trade on eToro (ad)Why investors are watching
Ocugen is a micro-cap company, so this Phase 1/2 trial of OCU400, a gene therapy for three inherited retinal diseases, is a core value driver. The trial tests safety and efficacy in 22 to 24 patients, and a positive readout could validate the therapy's broad approach across multiple mutations. For a company this size, the result of this small study carries outsized weight.
If it works: A positive safety and efficacy result could position OCU400 as a promising treatment for multiple forms of blindness, potentially attracting partners or funding. It could also support the company's path toward larger trials and eventual regulatory discussions.
If it fails: The trial could fail to show meaningful vision improvement or reveal safety problems, which would likely set the program back. Early-stage trials often fail, and a negative result for a micro-cap company could be severe, as the company has few other assets to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a single injection create Cancer-Fighting cells inside the body?
Cure Recruiting nowThis Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety and tolerability of SL1617 Injection in patients with relapsed or refractory B-cell lymphoma. SL1617 is an investigational in vivo CAR T-cell immunotherapy targeting CD19 and CD20, util…
Results expected Apr 2027 (estimated)
Phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
Cure Recruiting nowThis is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally advanced esophageal cancer. A total of 44 patients with …
Results expected Apr 2027 (estimated)
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Two-Drug combo aims to wipe out breast cancer before surgery in BRCA carriers
Cure Recruiting nowThis study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoad…
Results expected Apr 2027 (estimated)
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
Gene therapy trial aims to stop duchenne in its tracks
Disease control Recruiting nowThis is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participan…
Results expected May 2027 (estimated)
Phase 1/2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
Result impactHighMicro-cap Phase 2 Readout in ~8 moA small company. This result carries real weight for it.
Solid Biosciences Inc. · SLDB NASDAQ Trade on eToro (ad)Why investors are watching
Solid Biosciences is a very small company, so this early-stage trial of its one-time gene therapy SGT-003 for Duchenne muscular dystrophy is its main value driver. The trial tests safety and whether a single infusion helps boys with the disease, with results from the youngest age groups expected first. For a micro-cap, this readout will largely determine how investors view the company's future.
If it works: If the therapy shows a good safety profile and signs that it helps muscle function, the company could advance to later-stage testing and attract partnership interest. A positive result would validate its main asset and support the company's continued operation.
If it fails: Gene therapies often fail in early trials, and safety problems or weak efficacy data could force the company to halt development. A delay in enrollment or a poor readout could sharply reduce the company's prospects, since it has few other products in the pipeline.
AI-written from the trial record. Speculative, and not investment advice.
-
Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
Cure Recruiting nowThis phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or h…
Results expected May 2027 (estimated)
Phase 1 • Sponsor: University of California, Davis • Aim: Cure
Last updated Jul 19, 2026 00:00 UTC
-
Can a gene therapy restore natural hearing after cochlear implants?
Cure OngoingThis study will evaluate the safety, tolerability, and efficacy of EA0010 injection in patients with OTOF-related hearing loss who have already undergone cochlear implantation. Conventional gene therapy generally excludes cochlear implant recipients, based on the concern that the…
Results expected May 2027 (estimated)
Sponsor: Shanghai EmayGene Technology Co., Ltd • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
Prevention Recruiting nowThe AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and…
Results expected Jun 2027 (estimated)
Sponsor: Clinton Health Access Initiative Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Mind over matter: can a wireless brain implant restore control for the paralyzed?
Disease control Recruiting nowObjectives of Study: This trial aims to evaluate the safety and efficacy of an implantable wireless brain-computer interface system in patients with tetraplegia resulting from spinal cord injury.
Results expected Jun 2027 (estimated)
Sponsor: BCIFlex Medical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can engineered immune cells tackle resistant blood cancers?
Disease control Recruiting nowThe purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies
Results expected Jun 2027 (estimated)
Phase 1 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowDNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict the cancer signal origin (CSO) from a single fluid…
Results expected Jun 2027 (estimated)
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
CRISPR stem cell therapy shows promise for kids with sickle cell
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Results expected Jun 2027 (estimated)
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~9 moA large company. One readout moves the needle only so far.
-
Lab-Grown skin could transform burn healing
Cure Recruiting nowThis multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as…
Results expected Jun 2027 (estimated)
Phase 3 • Sponsor: CUTISS AG • Aim: Cure
Last updated Aug 12, 2026 00:00 UTC
-
Engineered immune cells take aim at a shared marker in two blood cancers
Cure Recruiting nowThis is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
Results expected Jun 2027 (estimated)
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Aug 30, 2026 00:00 UTC
-
Can engineered immune cells beat tough B-Cell cancers?
Disease control OngoingThe purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this d…
Results expected Jul 2027 (estimated)
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Gene-Editing shot aims to halt rare nerve disease in phase 3 trial
Disease control Recruiting nowThis study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Results expected Jul 2027 (estimated)
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
Intellia Therapeutics · NTLA NASDAQ Trade on eToro (ad)Result impactModerateMid-cap Phase 3, decisive Readout in ~9 moA mid-sized company with other programmes alongside this one.
-
Can a daily injection restore hand function after spinal cord injury?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and dai…
Results expected Jul 2027 (estimated)
Phase 3 • Sponsor: NervGen Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can engineered immune cells tackle an incurable childhood brain tumor?
Cure Recruiting nowThe CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of gen…
Results expected Aug 2027 (estimated)
Phase 1 • Sponsor: University College, London • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Ebola breakthrough? new trial aims to stop virus after exposure
Prevention Not yet recruitingEBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms. The trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD. Participants…
Results expected Aug 2027 (estimated)
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Can a single Gene-Editing injection stop a blinding corneal disease?
Cure Not yet recruitingThe goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy
Results expected Aug 2027 (estimated)
Phase 1/2 • Sponsor: GenEditBio Limited • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can a shot stop ALS before it starts? new trial tests tofersen in gene carriers
Disease control OngoingThe primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen a…
Results expected Aug 2027 (estimated)
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
Biogen · BIIB NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~11 moA large company. One readout moves the needle only so far.
-
Can a One-Time gene infusion rewrite the fate of PKU?
Cure Recruiting nowThis is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is a rAAV8 based vector carrying a functional copy of the human PAH gene. Par…
Results expected Aug 2027 (estimated)
Phase 1/2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 15, 2026 00:00 UTC
-
Can a single gene injection replace monthly eye shots for wet AMD?
Disease control Recruiting nowThis is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.
Results expected Aug 2027 (estimated)
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.